Preoperative intravitreal injection of conbercept improves the efficacy of neovascular glaucoma surgery

To investigate the therapeutic effects of intravitreal conbercept injection on neovascular glaucoma (NVG).

Sixty-seven patients with NVG were retrospectively selected and divided into a study group (n=34), which received intravitreal conbercept injection combined with trabeculectomy and panretinal photocoagulation; compared to a control group (n=33), which received trabeculectomy and panretinal photocoagulation only. The therapeutic effects, visual acuity, intraocular pressure, grade of iris neovascularization (NVI), pain score, complication rate, and anterior chamber angle were compared between the two groups.

The total effective rate in the study group was significantly higher than in the control group (97.06% vs. 81.82%, P<0.05). After 1 month of treatment, the study group showed significantly better visual acuity improvement and intraocular pressure control compared to the control group (both P<0.05). At 6 months of treatment, the proportion of patients with NVI grade 0-1 in the study group was significantly higher (94.11% vs. 48.48%, P<0.05). The proportion of patients with an anterior chamber angle ≥ grade 2 was also higher in the study group (70.59% vs. 39.39%, P<0.05). Additionally, the incidence of complications in the study group was lower (14.71% vs. 39.39%, P<0.05).

Preoperative intravitreal conbercept injection significantly improves NVI, visual acuity, and intraocular pressure control in patients with NVG, reduces the incidence of complications, and demonstrates both significant efficacy and good safety.